AstraZeneca
rare disease highlights expanding the potential of to adult patients with a progressive genetic condition phase trial improvement in adult patients by benign that develop on nerve sheaths leads to disfigurement motor dysfunction and pain us primary met statistically significant clinically meaningful volume reduction encouraging effect across pain severities low discontinuation rates rapid efficacy onset has the potential to address the high unmet need in adult patients with | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
23 of 38
Related slides by other companies
Nuvectis Pharma
Investor Presentation
August 2023
phase underway fast track designation | Nuvectis Pharma
AN2 Therapeutics
Investor Presentation
February 2025
potential to reduce mortality in patients soc alone | AN2 Therapeutics
AN2 Therapeutics
Investor Presentation
March 2025
potential to reduce mortality in patients soc alone | AN2 Therapeutics
Kymera
Investor Presentation
August 2023
part summary | Kymera
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io